Skip to main content
SpringerLink
Log in

Pulslichttherapie („intense pulsed light“) als Therapieoption bei der Behandlung der Meibom-Drüsen-Dysfunktion

Intense pulsed light (IPL) as a therapeutic option for Meibomian gland dysfunction

  • Das diagnostische und therapeutische Prinzip
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Die Meibom-Drüsen-Dysfunktion (MDD) ist eine häufige Ursache für die Entstehung des trockenen Auges. Die IPL(„intense pulsed light“)-Therapie stellt eine neue, zugelassene Behandlungsmethode dar. Der Behandlungszyklus sieht 2 bis 4 Sitzungen vor, bei denen Lichtimpulse im Bereich des Unterlids und des temporalen Lidwinkels appliziert werden. Bei der Therapie handelt es sich um eine sichere Behandlungsform bei Befolgung der vorgeschriebenen Sicherheitsvorkehrungen. In aktuellen Studien wird sowohl von einer Besserung der subjektiven Beschwerden als auch der objektiv messbaren klinischen Parameter berichtet.

Abstract

Meibomian gland dysfunction (MGD) is a common cause of dry eye disease. Intense pulsed light (IPL) treatment is a new and approved therapeutic option for MGD. The treatment consists of 2–4 sessions where light impulses are applied to the lower lid and temporal lid margin. The IPL technique is a safe form of treatment when the required safety precautions are followed. Current studies document an improvement of patients’ subjective symptoms and objectively measured clinical parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Messmer EM (2015) The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 112(5):71–81 (quiz 82)

    PubMed  PubMed Central  Google Scholar 

  2. Chia EM et al (2003) Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Exp Ophthalmol 31(3):229–232

    Article  PubMed  Google Scholar 

  3. Nelson JD et al (2011) The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 52(4):1930–1937

    Article  PubMed  PubMed Central  Google Scholar 

  4. Viso E et al (2012) Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci 53(6):2601–2606

    Article  PubMed  Google Scholar 

  5. Bron AJ et al (2014) Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf 12(2 Suppl):S1–S31

    Article  PubMed  Google Scholar 

  6. Romero JM et al (2004) Conservative treatment of meibomian gland dysfunction. Eye Contact Lens 30(1):14–19

    Article  PubMed  Google Scholar 

  7. Craig JP, Blades K, Patel S (1995) Tear lipid layer structure and stability following expression of the meibomian glands. Ophthalmic Physiol Opt 15(6):569–574

    Article  CAS  PubMed  Google Scholar 

  8. Bilkhu PS, Naroo SA, Wolffsohn JS (2014) Effect of a commercially available warm compress on eyelid temperature and tear film in healthy eyes. Optom Vis Sci 91(2):163–170

    PubMed  Google Scholar 

  9. Sobolewska B et al (2014) Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea 33(3):257–260

    Article  PubMed  Google Scholar 

  10. Geerling G et al (2011) The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 52(4):2050–2064

    Article  PubMed  PubMed Central  Google Scholar 

  11. Yu J, Asche CV, Fairchild CJ (2011) The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 30(4):379–387

    Article  PubMed  Google Scholar 

  12. Papageorgiou P et al (2008) Treatment of rosacea with intense pulsed light: significant improvement and long-lasting results. Br J Dermatol 159(3):628–632

    Article  CAS  PubMed  Google Scholar 

  13. Raulin C, Greve B, Grema H (2003) IPL technology: a review. Lasers Surg Med 32(2):78–87

    Article  PubMed  Google Scholar 

  14. Craig JP, Chen YH, Turnbull PR (2015) Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 56(3):1965–1970

    Article  PubMed  Google Scholar 

  15. Dell SJ et al (2017) Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction. Clin Ophthalmol 11:817–827

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Toyos R, McGill W, Briscoe D (2015) Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg 33(1):41–46

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kalangara JP et al (2016) Burning eye syndrome: Do neuropathic pain mechanisms underlie chronic dry eye? Pain Med 17(4):746–755

    PubMed  Google Scholar 

  18. Irvine J et al (2004) Double-blind randomized controlled trial of low-level laser therapy in carpal tunnel syndrome. Muscle Nerve 30(2):182–187

    Article  PubMed  Google Scholar 

  19. de Godoy CH et al (2013) Evaluation of effect of low-level laser therapy on adolescents with temporomandibular disorder: study protocol for a randomized controlled trial. Trials 14:229

    Article  PubMed  Google Scholar 

  20. Padua L et al (1998) Noninvasive laser neurolysis in carpal tunnel syndrome. Muscle Nerve 21(9):1232–1233

    Article  CAS  PubMed  Google Scholar 

  21. Kam WR, Sullivan DA (2011) Neurotransmitter influence on human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci 52(12):8543–8548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Chung CW, Tigges M, Stone RA (1996) Peptidergic innervation of the primate meibomian gland. Invest Ophthalmol Vis Sci 37(1):238–245

    CAS  PubMed  Google Scholar 

  23. DeLong MR, Benabid AL (2014) Discovery of high-frequency deep brain stimulation for treatment of Parkinson disease: 2014 Lasker Award. JAMA 312(11):1093–1094

    Article  CAS  PubMed  Google Scholar 

  24. Gupta A et al (2013) Shining light on nanotechnology to help repair and regeneration. Biotechnol Adv 31(5):607–631

    Article  CAS  PubMed  Google Scholar 

  25. Passarella S, Karu T (2014) Absorption of monochromatic and narrow band radiation in the visible and near IR by both mitochondrial and non-mitochondrial photoacceptors results in photobiomodulation. J Photochem Photobiol B 140:344–358

    Article  CAS  Google Scholar 

  26. Yadav A, Gupta A (2017) Noninvasive red and near-infrared wavelength-induced photobiomodulation: promoting impaired cutaneous wound healing. Photodermatol Photoimmunol Photomed 33(1):4–13

    Article  PubMed  Google Scholar 

  27. Mosca RC et al (2019) Photobiomodulation therapy for wound care: a potent, noninvasive, photoceutical approach. Adv Skin Wound Care 32(4):157–167

    Article  PubMed  Google Scholar 

  28. Roberts WE (2009) Skin type classification systems old and new. Dermatol Clin 27(4):529–533, viii

    Article  CAS  PubMed  Google Scholar 

  29. Gupta PK et al (2016) Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Can J Ophthalmol 51(4):249–253

    Article  PubMed  Google Scholar 

  30. Jiang X et al (2016) Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. J Ophthalmol 2016:1910694

    PubMed  PubMed Central  Google Scholar 

  31. Lee WW et al (2011) Ocular damage secondary to intense pulse light therapy to the face. Ophthalmic Plast Reconstr Surg 27(4):263–265

    Article  PubMed  Google Scholar 

  32. Jewsbury H, Morgan F (2012) Uveitis and iris photoablation secondary to intense pulsed light therapy. Can J Ophthalmol 47(4):e13–4

    Article  PubMed  Google Scholar 

  33. Craig JP et al (2017) TFOS DEWS II report executive summary. Ocul Surf 15(4):802–812

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Augenklinik, Klinikum der Universität München, Campus Innenstadt, Mathildenstr. 8, 80336, München, Deutschland

    A. Schuh,  S. Priglinger &  E. M. Messmer

Authors
  1. A. Schuh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Priglinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. M. Messmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Schuh.

Ethics declarations

Interessenkonflikt

A. Schuh, S. Priglinger und E.M. Messmer geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schuh, A., Priglinger, S. & Messmer, E.M. Pulslichttherapie („intense pulsed light“) als Therapieoption bei der Behandlung der Meibom-Drüsen-Dysfunktion. Ophthalmologe 116, 982–988 (2019). https://doi.org/10.1007/s00347-019-00955-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-019-00955-z

Schlüsselwörter

Keywords

Search

Navigation